A multicenter, randomized, double-blind, placebo-controlled phase III study of apatinib or placebo plus gefitinib as first-line treatment in patients with EGFR-mutant advanced non-small cell lung cancer (NSCLC)

被引：1
|
作者：
Zhao, Hongyun
Zhang, Zhonghan
Luo, Fan
Ma, Yuxiang
Fang, Wenfeng
Yang, Yunpeng
Zhang, Yang
Huang, Yan
Zhang, Li
机构：
[1] Sun Yat Sen Univ, Caner Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS9116
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9116
引用
收藏
页数：2
相关论文
共 50 条
  • [1] The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706)
    Zhang, Zhonghan
    Luo, Fan
    Zhang, Yang
    Ma, Yuxiang
    Hong, Shaodong
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    CANCER COMMUNICATIONS, 2019, 39 (01):
  • [2] ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)
    Zhang, L.
    Zhao, H.
    Zhang, Z.
    Yao, W.
    Min, X.
    Gu, K.
    Yu, G.
    Cheng, C.
    Cui, J.
    Miao, L.
    Song, X.
    Zhang, L.
    Yuan, X.
    Fang, Y.
    Fu, X.
    Hu, C.
    Zhu, X.
    Fan, Y.
    Yu, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S1181 - S1181
  • [3] BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
    Zhou, Caicun
    Wu, Yi-Long
    Chen, Gongyan
    Liu, Xiaoqing
    Zhu, Yunzhong
    Lu, Shun
    Feng, Jifeng
    He, Jianxing
    Han, Baohui
    Wang, Jie
    Jiang, Guoliang
    Hu, Chunhong
    Zhang, Hao
    Cheng, Gang
    Song, Xiangqun
    Lu, You
    Pan, Hongming
    Zheng, Wenjuan
    Yin, Anny-Yue
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (19) : 2197 - U108
  • [4] Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
    Zhao, Hongyun
    Yao, Wenxiu
    Min, Xuhong
    Gu, Kangsheng
    Yu, Guohua
    Zhang, Zhonghan
    Cui, Jiuwei
    Miao, Liyun
    Zhang, Li
    Yuan, Xia
    Fang, Yong
    Fu, Xiuhua
    Hu, Chengping
    Zhu, Xiaoli
    Fan, Yun
    Yu, Qitao
    Wu, Gang
    Jiang, Ou
    Du, Xiuping
    Liu, Jiwei
    Gu, Wei
    Hou, Zhiguo
    Wang, Quanren
    Zheng, Rongrong
    Zhou, Xianfeng
    Zhang, Li
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1533 - 1546
  • [5] Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
    He, Yong
    Li, Li
    Jiang, Liyan
    Wang, Yubo
    Zhao, Yizhuo
    Zhang, Xiaoju
    Wu, Guoming
    Zhou, Xiangdong
    Sun, Jianguo
    Bai, Jun
    Ren, Biyong
    Tian, Kun
    Xu, Zhi
    Xiao, Hualiang
    Zhou, Qi
    Han, Rui
    Chen, Hengyi
    Wang, Haidong
    Yang, Zhenzhou
    Gao, Chan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [6] BEYOND: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PHASE III STUDY OF FIRST-LINE CARBOPLATIN/PACLITAXEL (CP) PLUS BEVACIZUMAB (BV) OR PLACEBO (PL) IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Zhou, Caicun
    Chen, Gongyan
    Liu, Xiaoqing
    Zhu, Yunzhong
    Lu, Shun
    Feng, Jifeng
    He, Jianxing
    Han, Baohui
    Wang, Jie
    Jiang, Guoliang
    Hu, Chunhong
    Zhang, Hao
    Cheng, Gang
    Song, Xiangqun
    Lu, You
    Pan, Hongming
    Zheng, Wenjuan
    Yin, Anny-Yue
    Wu, Yi-Long
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S293 - S293
  • [7] Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy
    Volovat, Constantin
    Bondarenko, Igor M.
    Gladkov, Oleg A.
    Elsaesser, Reiner
    Buchner, Anton
    Bias, Peter
    Mueller, Udo
    SPRINGERPLUS, 2015, 4
  • [8] AVAGAST: A randomized, double-blind, placebo-controlled, phase III study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)
    Kang, Y.
    Ohtsu, A.
    Van Cutsem, E.
    Rha, S. Y.
    Sawaki, A.
    Park, S.
    Lim, H.
    Wu, J.
    Langer, B.
    Shah, M. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (18)
  • [9] Randomized, double-blind, placebo-controlled, phase III multicentre study of paclitaxel plus carboplatin (TC) versus TC plus endostar in patients with advanced non-small cell lung cancer (NSCLC)
    Han Baohui
    Xiu Qingyu
    Wang Huiming
    Luo Yi
    Bai Chunxue
    Guo Shuliang
    Liu Wenchao
    Zhuang Zhixiang
    Zhang Yang
    Zhou Jianying
    Jing Xianqiao
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S353 - S354
  • [10] Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first-line treatment for advanced EGFR-mutant non-small cell lung cancer
    Zhang, Zhonghan
    Zhang, Yang
    Luo, Fan
    Ma, Yuxiang
    Fang, Wenfeng
    Zhan, Jing
    Li, Su
    Yang, Yunpeng
    Zhao, Yuanyuan
    Hong, Shaodong
    Zhou, Ting
    Zhang, Yaxiong
    Zhao, Shen
    Huang, Yan
    Zhao, Hongyun
    Zhang, Li
    CLINICAL AND TRANSLATIONAL MEDICINE, 2020, 10 (02):
12345